ClinicalTrials.gg
RecruitingNCT07760779ANOWSMUpdated Nov 6, 2026

Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness

An interventional study of Brief behavioral treatment of insomnia and MI in Nocturia and Insomnia, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia.

To study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy.

The study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are:

  1. do these treatments reduce the frequency of nighttime awakenings to void
  2. do these treatments reduce the volume of nighttime urine production
  3. do these treatments improve sleep quality

Frequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.

Read the detailed description

Nocturia, or waking at night to void, and poor sleep are prevalent and comorbid conditions in the elderly. Nocturia affects up to 70% of those over age 60, and over 75% of the older adults with poor sleep report nocturia as the main reason. Nocturia increases risk for falls, fractures, depression, institutionalization, and death. Poor sleep and nocturia have a bidirectional relationship and are mutually exacerbating. Nocturnal polyuria (NP) or excess urine production during sleep is the major contributor to nocturia in the elderly and poor sleep is known to cause NP. Vasopressin and aldosterone peak during sleep, causing sodium and water reabsorption in renal tubuli, which leads to decrease in nighttime urine production. Sleep loss leads to attenuation of the sleep time release of these hormones, resulting in natriuresis and diuresis causing NP.

Brief behavioral treatment of insomnia (BBTI- a brief 4-week, efficacious behavioral treatment for insomnia) is effective in addressing sleep and nocturia. Investigators found in their recently concluded pilot trial among older adults with comorbid nocturia (≥2/night) and poor sleep, that BBTI improved nocturia more than control (-0.9 vs -0.3, p=.016). Compared to control, BBTI improved subjective insomnia severity index (-5.9 vs -2.5, p=.02). Additionally, BBTI also improved NP: % of 24h urine volume excreted at night decreased in BBTI vs control (-7.1±13%, p=.001 vs -4±11, p=.08). Although BBTI is brief and effective for nocturia, adherence to behavioral sleep treatments among patients with chronic conditions (poor sleep, nocturia) is disappointingly low compared to patients with acute conditions, particularly several months after therapy. Moreover, the time and personnel needed to train professionals and to administer the intervention has limited the scalability of this otherwise promising treatment. Alternatives to boost treatment adherence and maintain benefit need to be investigated.

Recently the investigators trialed brief mindfulness (MI) training alone or paired with transcranial direct current stimulation (tDCS) in older women with urinary incontinence to enhance cognitive control over bladder symptoms. Of these women, those who had nocturia (≥1/night) and received MI training alone experienced improvement in nocturia (-0.5±0.6, p=0.005) with a concurrent increase in FUSP (39.8±70.2 minutes, p=0.02). Interestingly, effect of MI on nocturia and FUSP were similar to that seen with BBTI. MI requires only brief training followed by convenient at-home use. It was well liked in our study with an acceptability of 85.6 and compliance of 94.4 on a 1-100 Likert scale indicating MI may be a simpler and scalable modality either alone or to augment BBTI for reducing nocturia in older women.

This study a randomized pilot trial in older women with interrupted sleep due to nocturia to examine the effect of BBTI and MI on nocturia, nighttime urine production, and sleep quality at 4-week (post-intervention) and 3- and 6-months later. The investigators postulate that both interventions, individually and in combination, will be beneficial, and the combined treatment will lead to sustained treatment effects at 3- and 6-months.

The study will include older women with nocturia. Sleep will be assessed subjectively with the Pittsburgh Sleep Quality Index (PSQI) and objectively using Zmachine®, an FDA cleared in-home single channel EEG device, and a 3-day bladder-sleep diary that concurrently assesses sleep and voiding pattern including frequency and volume during day and night. Participants will be randomized to one of the 4 groups in a 2x2 factorial design: i) BBTI, ii) MI, iii) BBTI+MI or iv) control. Participants will repeat the study measures at 4 weeks, and 3- and 6-months.

The study aims to explore the effects of MI and BBTI. Hypothesis: Compared to control, BBTI and/or MI groups will result in greater improvement in 1) nocturia, 2) volume of nighttime urine volume, and 3) sleep quality at 4 weeks with the combined BBTI+MI intervention conferring greater benefits and sustained treatment effects at 3- and 6-months.

This study will be the first RCT to evaluate the effect of BBTI and MI, individually and combined on nocturia and sleep, and to assess durability of benefit. The results will provide novel information regarding the promise of efficient cost-effective, and easy to disseminate means of treating nocturia in older women and facilitate confirmatory trial to provide definitive evidence and develop clinically acceptable treatment protocols.

02

Conditions studied

03

In context

Nocturia

134 studies on the registry are indexed under Nocturia; 22 are open to participants now.

This study's planned enrollment of 80 is above the median of 71 across 108 interventional studies indexed under Nocturia.

Browse Nocturia studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Age > or =65 years
  • Nocturia ≥2/night
  • Poor sleep (Insomnia Severity Index ≥8)
  • (including trail making) >26

Exclusion criteria

Exclusion Criteria:

  • Conditions that affect bladder function: Multiple sclerosis, Alzheimer's disease, spinal cord injury, urethral obstruction, urinary retention, interstitial cystitis, bladder cancer, radiation to the pelvic area, bladder surgery, current or uncontrolled chronic or recurrent bowel issues, bacterial endocarditis
  • cardiac or respiratory disease that limits daily function
  • Unstable or acute medical condition:

    - Any acute medical condition that requires immediate treatment such that it would interfere with the study protocol; Each instance will be assessed on a case-by-case basis by our study physician who may postpone a participant's enrollment; stably managed chronic conditions are exempt from this exclusion.

  • Untreated, current, severe psychiatric condition (assessed during Visit 1a- medical history)
  • Post void residual ≥ 200ml- assessed during baseline visit
  • Currently diagnosed and/or untreated obstructive sleep apnea, untreated restless leg syndrome, untreated parasomnia
  • Untreated or poorly controlled fluid overload conditions like CHF, diabetes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Control

    Behavioral: Control

  • Experimental
    BBTI

    Brief behavioral treatment of insomnia

    Behavioral: Brief behavioral treatment of insomnia

  • Experimental
    MI

    Brief mindfulness

    Behavioral: MI

  • Experimental
    BBTI+MI

    Brief behavioral treatment of insomnia and brief mindfulness

    Behavioral: BBTI+MI

Interventions

  • BehavioralBrief behavioral treatment of insomnia

    BBTI: will entail a 45- to 60-minute individual intervention session with instructions regarding sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. This education provides the rationale for the 4 main interventions of BBTI: 1. reduce time in bed; 2. get up at the same time every day, regardless of sleep duration; 3. do not go to bed unless sleepy; and 4. do not stay in bed unless asleep

  • BehavioralMI

    Participants in the MI group will be trained to engage in a brief mindfulness method involving body scan with acceptance language training.

  • BehavioralControl

    The control condition is intended to emulate the behavioral treatment information generally available to patients.

  • BehavioralBBTI+MI

    Participants in this arm will receive BBTI as well as MI training.

06

What researchers measure

Primary outcomes

  1. Nocturia

    number of nighttime awakenings to void

    Time frame: 4 weeks, 3- and 6-months post-intervention

Other outcomes

  1. Nocturnal polyuria index (NPi)

    percentage of 24-hour urine volume excreted at night

    Time frame: 4 weeks, 3- and 6-months post-intervention

  2. Pittsburgh Sleep Quality Index (PSQI)

    Self-reported sleep quality questionnaire scored by grouping 19 self-rated questions into seven component scores, summing them into a global score (0 to 21)\> PSQI score \>5 Indicates significant, poor sleep quality and clinical sleep disturbance.

    Time frame: 4-weeks, 3- and 6-month post intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification may be shared with other researchers.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Following publication, no end date

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
University of Pittsburgh is now Recruiting
Nov 6, 2026
Start date
Sep 15, 2026→Oct 15, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    University of Pittsburgh is now Recruiting
    Start date Sep 15, 2026→Oct 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07760779
Responsible party
Shachi Tyagi (Assistant Professor, University of Pittsburgh) — Principal investigator
First posted
Aug 12, 2026
Start date
Oct 15, 2026
Primary completion
Oct 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Shachi Tyagi, MD, MS
Contact
sht55@pitt.edu
14126471274
Becky D Clarkson, PhD
Contact
bdc29@pitt.edu
4126471270
Shachi Tyagi, MD, MS
principal investigator · University of Pittsburgh
Shachi Tyagi, MD, MS
study chair · University of Pittsburgh
Becky D Clarkson, PhD
study director · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion